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ABSTRACT
Chronic non-communicable diseases have become a pandemic public problem in the 21st century, causing enormous
burden on the economy, health and quality of life of societies. The role of a chronic inflammatory state in the pathogenesis
of chronic disease has been more comprehensively recognized by recent findings. The new paradigm ‘metaflammation’
focuses on metabolism-induced (high fat or fructose-based diet or excessive calorie intake) chronic inflammation. There is
a close correlation between the increased incidence of chronic kidney disease (CKD) and chronic heart failure with both
increased inflammatory marker levels and western-type diet. In this review we describe the concept of metaflammation, its
role in the development of CKD and chronic heart disease, the molecular and signalling pathways involved and the
therapeutic consequences.
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INTRODUCTION
Excessive nutrient intake and chronic non-communicable met-
abolic diseases are prominent hallmarks of the 21st century.
Noticeably, chronic heart failure (CHF) is one of the largest
pandemic health problems, involving >26 million people world-
wide [1]. Its incidence and prevalence are increasing in associa-
tion with modern lifestyles. It is estimated that 8 million
patients have CHF in the USA alone, and its prevalence is
expected to increase by 46% by 2030. In 2012, its economic bur-
den on the USA reached $31 billion and is expected to increase
by 127% in 2012–30 [1]. Likewise, chronic kidney disease (CKD)
represents another major public health problem imposing re-
markable economic and social burdens globally. CKD also has
indirect impacts on society by increasing the severity of morbid-
ities, including cardiovascular disease (CVD), diabetes, hyper-
tension, human immunodeficiency virus and malaria [2, 3].
Indeed, CKD is an independent risk factor for CVD morbidity
and mortality [4–6]. Remarkably, the Global Burden of Disease
2015 study directly attributed 1.2 million deaths, 19 million dis-
ability-adjusted life years and 18 million years of life lost from
CVD to CKD [3, 7]. The Global Burden of Disease study further
detected 5–10 million annual deaths from CKD. Indeed, the
worldwide prevalence of CKD is 3–18%, translating to 500 mil-
lion patients [8]. In some countries, CKD was estimated to be-
come the second leading cause of death after Alzheimer’s
disease by 2100 [9]. Knowledge of the aetiology and pathophysi-
ology of CKD and CHF is required to tailor more efficient, tar-
geted and individualized treatments [10].
In recent years, multiple studies have supported a patho-
genic role of systemic chronic inflammatory conditions on
many chronic diseases: inflammaging [11–15]. Inflammation is
essential to protect the body against pathogens and also to pro-
mote healing, remodelling and renewal of tissues. However, the
outcome of inflammatory activation depends on its duration
and severity and whether it is appropriate for the nature and
magnitude of the insult. During evolution, acute and adequate
inflammatory responses provided a survival advantage and
defense against pathogens. However, chronic, sterile and low-
grade inflammation does not have a role in evolutionary devel-
opment. The naturally protective inflammatory state can
become an unfavourable condition that promotes further tissue
injury in the long term [16, 17].
Recently a new paradigm called metaflammation (also
termed metainflammation) has emerged and is suggested to
play a role in various chronic diseases including CHF and CKD.
In this review we first define metaflammation and then explore
the role of metaflammation in the development and progres-
sion of CHF and CKD and the therapeutic implications.
Metaflammation
PubMed first recorded use of the term metaflammation in 2008
[18]. More recently, it was defined as a chronic low-grade in-
flammatory state induced by alterations in metabolism [17].
The complex link between body nutrition status, metabolic
pathways and immune signalling has been preserved, with
roots back to Drosophila, as an evolutionary adaptation to star-
vation. For example, activation of innate immune system com-
ponents such as tumour necrosis factor (TNF) and Toll-like
receptors (TLRs) blocks insulin pathway signalling through c-
Jun N-terminal kinase (JNK) and myeloid differentiation primary
response gene (MyD88) pathways. This may be one of the multi-
ple links between the inflammatory state and nutritional status
[17]. As early as 1983, TNF-a secreted from macrophages was
shown to induce insulin resistance in adipocytes, supporting a
close link between inflammation and metabolic syndrome [19].
The presence of macrophage infiltration in obese mice adipose
tissue further supported this hypothesis and became an impor-
tant milestone to understand the pathophysiology of metabolic
syndrome [17]. Free fatty acid exposure triggers polarization of
adipose tissue macrophages to M1-type macrophages, which in-
hibit insulin function [17]. The transformation of resident adi-
pose tissue quiescent macrophages to active macrophages
initiates further recruitment of macrophages and secretion of
inflammatory molecules, including monocyte chemoattractant
protein-1, interleukin-6 (IL-6) and TNF [20]. Insulin resistance
has been linked to immune system dysfunctions, including thy-
mic atrophy, impaired number and function of regulatory T
cells (Tregs), natural killer cells, and dendritic cells [21].
Additionally, in obese mice, adipose tissue regulatory B cells are
decreased. These cells secrete IL-10 and transforming growth
factor b1 (TGF-b1), which have anti-inflammatory properties
[21]. These observations may have therapeutic consequences.
As an example, induction or transfer of CD4þ latency-associated
peptide Tregs as immunotherapy decreased inflammation in
adipose tissue, hepatosteatosis and pancreatic islet cell hyper-
plasia [22].
The role of endoplasmic reticulum (ER) dysfunction in
metaflammation
The ER is a key organelle in the regulation of cellular and meta-
bolic homeostasis. Maintenance of the proteome consistency is
required for cell homoeostasis [23]. In the presence of misfolded
proteins, the ER unfolded protein response is activated to de-
crease cellular stress via increasing proper protein folding,
chaperone availability and misfolded protein clearance. ER
stress induces nuclear factor kappa light chain enhancer of acti-
vated B cells (NF-jB) signalling that regulates the immune and
inflammatory response system ranging from haematopoietic
cell production to cytokine secretion. ER stress results in an ex-
cessive inflammatory response, and the ER has an essential role
in lipid homoeostasis and regulation of insulin-induced signal-
ling pathways [23, 24]. In this regard, obesity-induced ER stress
impaired insulin signalling through serine phosphorylation of
insulin receptor substrate 1 and overactivation of JNK via inosi-
tol requiring enzyme 1 [25]. An oral chemical chaperone (4-phe-
nyl butyric acid or dimethylsulphoxide) reduced ER stress,
decreased hepatosteatosis and improved insulin sensitivity [26].
Inflammasome and metaflammation
The inflammasome is composed of multimeric proteins that ac-
tivate caspase-1 cleavage of pro-inflammatory cytokines IL-1b
and IL-18 in the presence of danger-associated molecular pat-
terns (DAMPs), infection, cellular/tissue damage or metabolic
dysregulation, resulting in pro-inflammatory cell death (i.e.
pyroptosis) [27]. Inflammasome and associated caspase and IL
systems are key modulators of metabolism and adipocyte func-
tion. Caspase-1 is overexpressed during adipocyte differentiation.
Mice deficient in caspase-1 or nucleotide-binding oligomerization
domain-like receptor protein 3 (NLRP3) (inflammasome compo-
nent) had better insulin sensitivity and adipocyte oxidation/me-
tabolism and mitochondrial function than wild-type mice [28].
Indeed, caspase-1 or inflammasome inhibitors have been pro-
posed as novel treatments for metabolic syndrome [28].
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High mobility group box 1 (HMGB1) is one component of
chromatin that stabilizes nucleosomes and changes DNA con-
figuration to facilitate transcription [29]. HMGB1 is released by
necrotic cells and activates the inflammasome in macrophages
by binding to receptors for advanced glycation end products
(RAGEs) [29, 30]. In this regard, anti-HMGB1 antibodies reduced
weight gain and liver inflammation, further supporting a role
for inflammation in metabolic syndrome [30]. Indeed, HMGB1 is
significantly elevated in CKD and correlates with glomerular fil-
tration rate (GFR) as well as with markers of inflammation and
malnutrition [31].
Epigenetics in metaflammation
Epigenetic changes [DNA methylation, post-translational his-
tone modifications and microRNAs (miRNAs)] modulate gene
expression and thus inflammatory and metabolic signalling
[32]. Epigenetic changes may be responsible for ‘metabolic
memory’, particularly in adipose tissue macrophages, which is
one of the key elements driving low-grade chronic inflamma-
tion [20]. Epigenetic changes facilitate the expression or repres-
sion of certain genes both acutely and chronically. Since
epigenetic modifications may be transferred to daughter cells,
there is the potential to perpetuate changes in gene transcrip-
tion. This may explain metabolic memory and long-term effects
of acute tissue injury. As an example, both inflammatory medi-
ators and albuminuria decrease kidney expression of the cardi-
oprotective, anti-ageing and anti-inflammatory hormone
through epigenetic changes that may be concerned with NF-jB
[33, 34]. For example, kidney Klotho downregulation persists
long after renal function has been recovered in acute kidney in-
jury [33]. Indeed, Klotho suppression has been proposed as a
key contributor to inflammaging in CKD [35] and epigenetic
modulation of Klotho expression improves kidney injury [36].
Epigenetic regulators in response to inflammatory signals also
regulate insulin resistance. Overexpression of the epigenomic
co-repressor G protein pathway suppressor 2 in obese mice
improves insulin resistance and reduces inflammation and
macrophage recruitment in adipose tissue [20].
Inflammation and metabolic disorders interplay with ge-
netic and epigenetic factors and have a key role in the develop-
ment of chronic non-transmissible diseases (Figure 1). Below,
we separately discuss these issues in cardiorenal disorders, in-
cluding CHF and CKD.
The adenosine monophosphate–activated protein kinase
(AMPK) pathway also plays an important role in the metabo-
lism, inflammation and CHF–CKD cascade. Recent studies sug-
gest that AMPK might act as an inflammatory repressor, and
inhibition of AMPK increases inflammation, especially in obese
humans [37]. In the same line, AMPK activation might suppress
inflammation by inhibition of the NF-jB pathway and overex-
pression of AMPK inhibits the NF-jB pathway in endothelial
cells [38]. Furthermore, adiponectin decreased angiotensin II–
induced cardiac hypertrophy by decreasing NF-jB activity in
rats, but this beneficial effect disappeared after AMPK inhibition
[39]. Experimental studies showed that the cardioprotective ef-
fect of metformin requires AMPK activation [40, 41]. Last but not
the least, the cardioprotective effect of statins might also be me-
diated at the molecular level by increasing AMPK and nitric ox-
ide production in human umbilical vein endothelial cells and in
mouse aortas and myocardium [42]. Thus the AMPK pathway
may be another mediator of metabolism inflammation, CKD
and CVD, and this issue needs further investigation.
Chronic heart disease
Recent evidence has shown a close relation between increased
inflammatory markers and CHF [43–45]. There is an ongoing dis-
cussion of whether systemic inflammation plays a role in the
pathogenesis of CHF, is a consequence of CHF, or both, contrib-
uting to a ‘vicious cycle’ of disease severity [46]. For example,
the serum TNF level increases in the decompensation phase of
CHF and is an independent prognostic factor for both cardiac
and non-cardiac-related mortality in CHF [16, 47]. Additionally,
TNF and IL-1b downregulate Caþ2-related gene expression, in-
cluding sarcoplasmic reticulum Caþ2 ATPase and Caþ2 release
channels; impair the efficiency of gap junction mechanisms,
leading to dysregulated electrical conduction and unsynchron-
ized contraction and have a negative inotropic effect on myo-
cytes, concluding with eccentric cardiomyocyte hypertrophy,
myocardial fibrosis, ventricular dilation and ultimate CHF [47,
48]. Inflammation- or CKD-driven Klotho deficiency also con-
tributes to cardiomyopathy, and recombinant a-Klotho prevents
and retards uraemic cardiomyopathy [49].
TNF-like weak inducer of apoptosis (TWEAK) is a member of
the TNF cytokine superfamily that activates the Fn14 receptor
and activates both the canonical (as TNF) and the non-
canonical (unlike TNF) pathways of NF-jB [50, 51]. In addition to
decreasing Klotho through epigenetic mechanisms, TWEAK di-
rectly promotes cardiac dysfunction and failure through down-
regulation of the mitochondrial biogenesis regulator PGC1a, an
action of TWEAK that also contributes to CKD [52, 53], and
increases vascular calcification [54]. In keeping with this, higher
serum TWEAK levels are associated with the severity of coro-
nary artery disease, particularly in CKD Stages 2 and 3 patients
[55], and predict mortality in haemodialysis patients [56]. Liver
TWEAK signalling is differentially activated by palm oil in asso-
ciation with insulin resistance [57] and in response to a high-fat
diet, and it contributes to liver steatosis, fibrosis and inflamma-
tion and insulin resistance [58].
In addition to IL-1b and TNF superfamily cytokines [59], IL-6
also contributes to CHF. Thus it decreases myocardial contrac-
tility and promotes cardiac hypertrophy and fibrosis leading to
diastolic dysfunction by signalling through Gp130 to activate
Janus kinase/signal transducer and activator of transcription 3
[47, 60]. IL-6 is the cytokine that best correlates with adverse
cardiovascular outcomes in CKD [61]. However, C-reactive
FIGURE 1: Postulated mechanisms between inflammation, insulin resistance, ER
stress and systemic diseases.
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protein (CRP) is the marker of systemic inflammation most
commonly used in clinical practice, and it associates with dia-
betes mellitus, atherosclerosis and CHF. A direct role of CRP on
CV injury has been suggested [62]. CHF and inflammation may
be further linked through endothelial dysfunction and haemo-
dynamic dysregulation via improper endothelial activation and
increased vascular stiffness [14, 16, 63–65]. Inflammation-
induced vascular permeability may cause fluid extravasation
and further amplify cardiac dysfunction [16]. Additionally, ve-
nous congestion due to CHF may trigger more pro-inflammatory
cytokine release, increase endotoxin absorption from the gut
and promote kidney dysfunction that, in turn, further promotes
inflammation and increased gut permeability [66, 67]. CHF is
also associated with an altered gut microbiota that correlates
with systemic inflammation in CHF [46, 68, 69].
Alteration of gut microbiota is another factor linking meta-
bolic disorders, inflammation and chronic diseases such as CKD
and CHF. Vaziri et al. [70] showed that the microbial composition
of the gut is highly different in end-stage renal disease (ESRD)
patients compared with healthy subjects. Due to changes like
diet and colonic transit time in CKD patients, microbial metabo-
lism moves towards a predominantly proteolytic fermentation.
The percentage of bacterial families possessing urease, uricase
and indole- and p-cresol-forming enzymes increase, whereas
the percentage of bacterial families possessing butyrate-
forming enzymes decreases in CKD patients. This increase of
protein fermentation occurs at the expense of carbohydrate fer-
mentation and disrupted epithelial barrier. This suggests that
altered microbial composition and metabolism may have a role
in the dysfunctional epithelial barrier, which is associated with
bacterial translocation and endotoxinaemia, increases in sys-
temic inflammation and the risk for CVD [71]. This altered dys-
function of the intestinal barrier in CKD. This pathophysiologic
process is now considered one of the mechanisms explaining
high cardiovascular burden in CKD patients.
With time, the vicious cycle between inflammation and CHF
becomes more and more prominent and eventually it may be
unbreakable [16]. Both TLRs and RAGEs are elemental pattern rec-
ognition receptors for detection of DAMPs, such as HMGB1 and
others. The metabolic syndrome–associated chronic inflammatory
state induces activation of TLR- and NF-jB-associated inflamma-
tory responses on cardiac myocytes, contributing to insulin resis-
tance, inflammation and further cardiomyocyte injury [46].
Metaflammation also contributes to endothelial dysfunction,
vascular calcification and atherosclerosis [72]. Dyslipidaemia
originating from metabolic syndrome [including decreased levels
of high-density lipoprotein and increased levels of triglycerides,
total cholesterol and low-density lipoprotein (LDL)] is an inde-
pendent risk factor for adverse cardiovascular outcomes [73, 74].
Atherogenic adipokines are also released by adipose tissue [72].
Metaflammation is also associated with mitochondrial dys-
function, decreasing energy availability and increasing mito-
chondrial reactive oxygen species (ROS) production [75]. Indeed,
energy metabolism is thought to be a key driver of diabetic car-
diomyopathy, and it has been proposed that an improved fuel
profile is a key contributor to the improved outcomes of
patients on sodium-glucose co-transporter 2 inhibitors [76].
Epigenetic modifications and CHF
Differentiating healthy cardiomyocytes during development and
failing or stressed cardiomyocytes share epigenetic modification
patterns [77]. During CHF, epigenetic modifications regulate the
expression of transcription factors, angiogenic factors and
natriuretic factors, among others [77–79]. Since there is an associ-
ation of increased DNA methylation levels with pathological hy-
pertrophy and impaired contractility in failing cardiomyocytes,
inhibition of DNA methylation has been proposed as a treatment
option for CHF since it has the potential to reverse pathologic nor-
epinephrine and Caþ2-induced cardiac fibrosis [79]. DNA methyl-
ation inhibitors are already in clinical use for malignancy [32].
Histone post-translational modifications have also been as-
sociated with metabolic syndrome, inflammation and heart dis-
ease. Of >50 known histone post-translational modifications,
acetylation and methylation are the best characterized. Histone
acetylation modulates gene expression associated with cardio-
myocyte function, inflammation and fibrosis [79]. Sirtuins are
histone/protein deacetylases that regulate mitochondrial func-
tion and cell survival. Specifically, SIRT1 and SIRT3 protect car-
diomyocytes from stress [80]. Histone deacetylase inhibitors
decrease cardiac fibrosis and hypertrophy and improved myofil-
ament Caþ2 sensitivity [81]. Trimethylation of histone H3 on ly-
sine 4 or lysine 9 were markedly different between normal
hearts and heart failure both in experimental animals and in
humans [82]. However, the potential therapeutic consequences
of this observation remain unexplored.
Altered messenger RNA expression also contributes to heart
failure. As an example, miR-208a, which is released into the cir-
culation during heart injury, is associated with the expression
of the a- myosin heavy chain and is a regulator of cardiac hyper-
trophy and conduction [83]. miR-208a is required for normal
cardiac function [84], but when overexpressed, it induced hyper-
trophy and arrhythmia [84]. In this regard, targeting miR-208a
by anti-miR protected Dahl hypertensive rats from
hypertension-induced heart failure [85]. Interestingly, miR-208a
targets mediator complex subunit 13 (MED13), one of compo-
nents of the mediator complex that regulates fatty acid, choles-
terol, lipid and cellular energy homoeostasis, increasing energy
expenditure [79, 86]. Cardiac-specific overexpression of MED13
or pharmacologic inhibition of miR-208a (leading to MED13
upregulation) in mice conferred resistance to high-fat diet-in-
duced obesity and showed an improvement in systemic insulin
sensitivity and glucose tolerance [86]. In summary, these stud-
ies demonstrated a close relationship between the epigenetic
regulation of cardiac function and metabolic diseases and a po-
tential of miR208-a inhibition in the treatment of cardiac and
chronic metabolic diseases. Upregulation of miR-23, miR24 and
miR-195 was also associated with cardiac hypertrophy and
ischaemic cardiomyopathy through the MAPK signalling path-
way [79, 87, 88]. The number and types of heart failure-related
miRNA or other epigenetic changes are rapidly increasing and
may provide novel therapeutic targets for CHF.
CKD. The role of chronic inflammation on the pathogenesis of
CKD and its complications is widely recognized [12, 89–91]. CKD
is a cause of low-grade chronic inflammation and chronic in-
flammation decreases kidney Klotho expression and increases
oxidative stress, adhesion molecules, aberrant matrix composi-
tion and fibrosis of renal tissue, leading to progressive renal
dysfunction [92].
Oxidative stress may have a role in the progression of kidney
disease independent from the aetiology. The formation of ROS
occurs both in the renal cortex and medulla. Increased ROS has
various effects, such as microinflammation, which is frequently
seen in CKD [93, 94]. Oxidative stress has been considered the
link between inflammation and CVD in CKD [95]. Oxidative
stress is closely related to endothelial dysfunction and endothe-
lial dysfunction, in turn, is closely related to arterial
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hypertension, arteriosclerosis and heart failure [96]. Undou
btedly, the most elaborated role of oxidative stress is acknowl-
edged in diabetic nephropathy (DN). This issue is very impor-
tant since DN is the most common form of CKD. Especially in
DN, mitochondrial dysfunction has been well demonstrated [97]
and antioxidant supplementation was beneficial in DN [98, 99].
Patients with metabolic syndrome have an increased fre-
quency of renal vascular sclerosis, tubulointerstitial fibrosis and
tubular atrophy [100, 101]. Despite the strong association of meta-
flammation and metabolic syndrome with CKD, further studies
are needed to elucidate the exact pathogenesis and
potential novel therapeutic implications. Several questions re-
main to be clarified: Does CKD per se originate from metaflamma-
tion? Does chronic inflammation accelerate a pre-existent CKD?
Does CKD worsen already existing metaflammation? Is this a vi-
cious cycle—and at what stage of CKD can it be arrested?
The observations regarding oxidative stress, CKD and CVD are
not confined in the context of diabetes and metabolic disorders.
The role of oxidative stress–related CVD is also evident in other
types of CKD. For example, a recent review by Andries et al. [102]
clearly demonstrated that excessive oxidative stress is closely as-
sociated with endothelial dysfunction and hypertension, even in
the early stages of autosomal dominant polycystic kidney disease.
Endothelial nitric oxide synthase uncoupling due to increased
asymmetric dimethylarginine and mitochondrial dysfunction are
postulated mechanisms linking oxidative stress and CVD in auto-
somal dominant polycystic kidney disease.
Among the drivers of tissue injury in the CKD metainflam-
matory environment, recent data have focused on the NLRP3
inflammasome, which contributes to western diet and fructose-
induced renal inflammation, renal cholesterol accumulation and
hyperuricaemia, as evidenced by protection in Nlrp3 knockout
mice [103, 104]. Tubular cell lipotoxicity induced by continuous
exposure to LDL cholesterol and long-term overnutrition was
characterized by intralysosomal lipid accumulation, lysosomal
dysfunction, oxidative stress and tubular dysfunction leading to
NLRP3 inflammasome activation that inhibited the sirtuin-1/
LKB1/AMPK pathway to dampened lipid breakdown, leading to a
vicious cycle of further phospholipid accumulation, oxidative
stress and mitochondrial damage [105]. In this regard, in a tran-
scriptomic study of a large cohort (n ¼ 95) of normal and fibrotic
human kidney tubules, inflammation and metabolism were the
top dysregulated pathways in the diseased kidneys. Specifically,
tubulointerstitial fibrosis samples had lower expression of key
enzymes and regulators of fatty acid oxidation and higher intra-
cellular lipid deposition. Indeed, fatty acid oxidation is the key
energy source in tubular cells and inhibition of fatty acid oxida-
tion in tubule epithelial cells caused ATP depletion, cell death,
dedifferentiation and intracellular lipid deposition [106].
The Chronic Renal Insufficiency Cohort (CRIC) study estab-
lished the link between impaired renal function [lower esti-
mated glomerular filtration rate (eGFR)] or kidney injury (higher
albuminuria) and levels of inflammatory markers, including IL-
1b, IL-6, TNF, CRP and fibrinogen [92]. There is evidence for all of
them being more than markers of risk by contributing to the
pathogenesis of CKD progression and cardiovascular complica-
tions [11]. CRP may have deleterious effects on renal blood flow
through the NF-jB pathway in endothelial cells leading to endo-
thelial dysfunction and triggering vasoconstriction through re-
cruitment of angiotensin-II and endothelin 1, and decreasing
nitric oxide synthesis [107]. Higher CRP and TNF levels were in-
dependently associated with accelerated renal function loss
[108] as well as with decreased survival in haemodialysis
patients [109, 110]. Fibrinogen may increase blood viscosity and
decrease microvascular flow as well as being a mitogen for renal
fibroblasts [52].
Further evidence for altered lipid metabolism in CKD pro-
gression and vascular injury is derived from the pleiotropic
actions of statins, which, beyond LDL reduction, can interfer
with intracellular prenylation processes, displaying anti-
inflammatory and anti-fibrotic properties [111–113]. Thus, in
CKD patients, atorvastatin decreased levels of inflammatory
marker (CRP, IL-1b and TNF) and improved cardiovascular func-
tion independent of its impact on lipid profile in CKD [114].
Epigenetics and CKD
In recent years, evidence has emerged on the role and impor-
tance of epigenetic modifiers on both embryonic kidney devel-
opment and acute kidney injury and CKD [115]. Abnormalities
in DNA methylation, histone modifications and miRNA have
been described and shown to contribute to CKD progression.
Genome-wide studies (GWASs) observed prominent differences
in DNA methylation of CpG sites between DN and healthy sub-
jects [116]. Demethylation of genes for methylenetetrahydrofo-
late reductase and connective tissue growth factor was a
predisposing factor for the development of DN [116]. Indeed, the
differentially methylated regions were associated with profi-
brotic genes [116]. Also, hyperglycaemia and oxidant stress in-
crease the expression of the histone methyl transferase ‘SET7’
that facilitates the transcription of profibrotic genes in DN [117].
Furthermore, changes in methylation patterns of mitochondria-
associated genes (peptidase, mitochondrial b subunit; translation
elongation factor, mitochondrial; AU RNA binding
methylglutaconyl-CoA hydratase) are seen in DN, suggesting the
connection between mitochondrial dysfunction and DN [117].
Ledo et al. [118] investigated novel genes in the vicinity of
CKD-associated single nucleotide polymorphisms (SNPs). They
showed a strong correlation between SNPs (FAM47E, PLXDC1,
ACSM2A/B, ACSM5 and MAGI2) and candidates for CKD devel-
opment [118]. In another study, Xu et al. [119] identified three
genes (NAT8B, CASP9 and MUC1) that have a causal effect on
eGFR [119]. Parsa et al. [120] performed a GWAS in the CRIC
study participants. CKD progression defined as change in eGFR
over time among 1331 blacks and 1476 whites with CKD status.
They identified 12 SNPs among black patients and 6 SNPs
among white patients. Among blacks without diabetes,
rs653747 in LINC00923 was associated with ESRD. In contrast,
rs931891 in LINC00923 associated with an eGFR decrease in
white patients without diabetes.
Histone deacetylase inhibitors reduced inflammation, fibro-
sis and expression of a-smooth muscle actin, collagen I, fibro-
nectin, TGF-b1 and NF-jB [117]. In addition to the well-known
acetylation and methylation of histones, a role for histone cro-
tonylation in nephroprotection was recently described [121].
Crotonate is a short-chain fatty acid produced by the gut micro-
biota [122]. Finally, various miRNAs have been implicated in the
pathogenesis of DN, including miRNA-25, miRNA-23b, miRNA-
21, miRNA-29a, miRNA-146a and others [123].
Role of mitochondrial dysfunction in CKD
Mitochondria have major regulatory functions in energy, Caþ2
and iron homoeostasis, inflammation, cell death pathways and
oxidative stress and mitochondrial dysfunction and have re-
ceived attention as a potential therapeutic target in kidney dis-
ease [124]. In particular, proximal tubular epithelial cells have
high energy requirements and oxygen consumption to support
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molecule secretion and reabsorption. Metabolic syndrome and
diet may disrupt this balance. As an example, even transient
postprandial hyperglycaemia may increase the glucose load in
proximal tubules and increase oxygen and energy requirements
to reabsorb filtered glucose, which through coupling to sodium
reabsorption also contributes to CHF [125]. Moreover, hypergly-
caemia can directly induce mitochondrial oxidative stress, con-
tributing to endothelial and tubular dysfunction, podocyte
injury and activation of apoptosis [126, 127]. DM-induced mito-
chondrial DNA oxidative stress causes endothelial dysfunction
and podocyte loss via endothelin 1/endothelin 1 receptor type
A signalling [126]. Treatment with the mitochondrial-targeted
potent antioxidant mitoTEMPO improved endothelial injury, al-
buminuria and glomerular sclerosis [126]. Additional mitochon-
drial protective strategies are undergoing clinical trials in
kidney and CVD [124].
Future perspectives. The increasing evidence of an impact of
diet-induced chronic inflammatory state on the initiation of
chronic diseases has led to the design of clinical trials targeting
inflammation in CKD and CVD (Figure 2). These range from
open-label investigator-initiated trials of non-expensive drugs
to large pharma-sponsored trials. As examples, pentoxifylline
has anti-inflammatory actions and in DN it decreased albumin-
uria, preserved GFR, decreased circulating and urinary TNF and
preserved Klotho levels in the circulation and in urine, in line
with a Klotho-preserving action in cells exposed to inflammatory
mediators of albumin [34, 128]. In another example, low-dose
aspirin increased the anti-inflammatory lipid 15-epi-lipoxin A4 in
CKD patients and decreased coronary and renal events [129]. In
this regard, several anti-inflammatory drugs are undergoing clin-
ical evaluation in DN [130]. On the other side of the spectrum, bio-
logical agents targeting specific cytokines have been proposed for
nephro and cardiovascular protection [59]. The most striking
demonstration of the feasibility and efficacy of this approach was
the Canakinumab Anti-inflammatory Thrombosis Outcomes
Study in patients with previous myocardial infarction and evi-
dence of systemic inflammation [131]. Targeting IL-1b with cana-
kinumab reduced non-fatal myocardial infarction, non-fatal
stroke and cardiovascular death [131]. Additional approaches in-
clude the use of low-dose immunosuppressive agents. In experi-
mental animals, mycophenolate mofetil reduced renal
inflammation, oxidative stress, endothelial dysfunction and hy-
pertension [132, 133]. Although mycophenolate mofetil is used in
clinical practice to treat autoimmune diseases, including primary
glomerulonephritis, vasculitis and lupus nephritis, as well as kid-
ney transplant recipients, its potential use as a non-specific anti-
inflammatory agent in non-immune CKD has not yet been tested.
Another non-specific immunosuppressant, low-dose methotrex-
ate, has been tested for cardiovascular protection. However,
among patients with stable atherosclerosis, low-dose methotrex-
ate did not reduce IL-1b, IL-6 or CRP or cardiovascular events
[134]. Antioxidant treatments to reduce mitochondrial oxidative
stress are another potential treatment option [124]. Lastly, epige-
netic modulation is coming of age. Modulators of DNA methyla-
tion and post-translational histone modifications are already in
clinical use, mainly in the oncology context [32]. Additionally,
inhibitors of bromodomain and extraterminal proteins, which
are readers of epigenetic clues, have been successfully used in ex-
perimental kidney injury and early clinical trials for CVD and
CKD have been promising [135]. RNA interference approaches, ei-
ther small-interfering RNAs or miRNA inhibitors (anti-miRs) or
mimics have been tested clinically [136]. Patisiran is an RNA in-
hibitor that improved multiple clinical manifestations of heredi-
tary transthyretin amyloidosis, a disease characterized by
neurological cardiac and kidney manifestations, and was ap-
proved by regulatory authorities in the summer of 2018 [137].
While this is a very specific condition, these studies validate the
feasibility of the approach. In any case, renal safety should be
monitored in routine clinical practice, given the kidney safety sig-
nals from miravirsen, an anti-miR-122 for hepatitis C virus infec-
tion [138]. Finally, dietary modification or the use of prebiotic or
probiotic approaches is another possibility [139].
CONCLUSION
Chronic inflammation induced by excessive nutrient intake and
metabolic syndrome has reached epidemic proportions in the
FIGURE 2: The interaction of the macroenvironment (in this case, western diet and lifestyle) and genetic predisposition determines the magnitude and type of meta-
bolic alterations, which in turn drives a change in the microenvironment through epigenetic modifications, oxidative stress, mitochondrial and lysosomal dysfunction
and an inflammatory response, leading to progressive tissue injury. Several positive feedback loops form vicious circles that increase the severity of tissue injury and
dysfunction, leading to cardiac and kidney disease progression. All contributing factors and pathways may be subject to therapeutic manipulation.
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21st century and is contributing to the increased prevalence
and mortality from CVD and CKD.
Metainflammation is defined as a chronic low-grade inflam-
matory state induced by alterations in metabolism and is linked
to CKD and CHF. Recent advances have identified key mediators
and pathways that link altered metabolism and chronic inflam-
mation with target organ injury. These include mitochondrial
dysfunction, oxidative stress, genetic and epigenetic changes
and altered gut microbiota. These recent findings have led to
the design of novel therapeutic strategies, some of which have
proved successful in Phase 3 clinical trials. A more detailed un-
derstanding of the cellular and molecular pathways involved
will increase the array of therapeutic tools that may stem the
current negative trend in mortality from CKD and CHF.
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